https://www.selleckchem.com/products/byl719.html
86, 95% CI 0.73-1.01, p=0.07). Shorter length of stay (LOS) (WMD-5.07, 95% CI-6.71 to-3.43, p0.001) was noted in ERAS group, without increasing 30-day readmission (RR 1.03, 95% CI 0.86-1.24, p=0.71) and mortality (RR 0.70, 95% CI 0.41-1.21, p=0.2. ERAS significantly reduced overall and minor morbidity, incidences of DGE, incisional and intra-abdominal infections, and shortened LOS in PD, without increasing 30-day readmission and mortality. However, more large-scale randomized controlled trials are still needed to confirm the findin
Like
Comment
Share
